Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug;32(8):5726-5727.
doi: 10.1245/s10434-025-17537-w. Epub 2025 May 27.

ASO Author Reflections: Stage-Specific Tumor Residual Thresholds Following Preoperative Therapies in Hepatocellular Carcinoma: Prognostic Implications and Tailored Management Strategies

Hongwei Xu  1   2 , Haili Zhang  1 , Yani Liu  1   3 , Haojun Wu  1 , Bo Li  1 , Kefei Chen  1 , Yonggang Wei  4
Affiliations

ASO Author Reflections: Stage-Specific Tumor Residual Thresholds Following Preoperative Therapies in Hepatocellular Carcinoma: Prognostic Implications and Tailored Management Strategies

Hongwei Xu et al. Ann Surg Oncol. 2025 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Disclosure: Hongwei Xu, Haili Zhang, Yani Liu, Haojun Wu, Bo Li, Kefei Chen, and Yonggang Wei have no conflicts of interest or disclaimers to declare that may be relevant to the contents of this study.

Similar articles

See all similar articles

Cited by

References

    1. Wu J-Y, Zhang Z-B, Zhou J-Y, et al. Outcomes of salvage surgery for initially unresectable hepatocellular carcinoma converted by transcatheter arterial chemoembolization combined with lenvatinib plus anti-PD-1 antibodies: a multicenter retrospective study. Liver Cancer. 2022;12(3):229–37. - DOI - PubMed - PMC
    1. Zeng Z-X, Wu J-Y, Wu J-Y, et al. Prognostic value of pathological response for patients with unresectable hepatocellular carcinoma undergoing conversion surgery. Liver Cancer. 2024;13(5):498–508. - DOI - PubMed - PMC
    1. D’Alessio A, Stefanini B, Blanter J, et al. Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis. Lancet Oncol. 2024;25(11):1465–75. - DOI - PubMed - PMC
    1. Xu H, Zhang H, Liu Y, et al. Prognostic impact of pathological response in patients with hepatocellular carcinoma following preoperative treatments. Ann Surg Oncol. 2025. https://doi.org/10.1245/s10434-025-17453-z . - DOI - PubMed - PMC

LinkOut - more resources